Key pathways in renal disease progression of experimental diabetes (Q38553926)

4 September 2017

1 reference

title

Key pathways in renal disease progression of experimental diabetes (English)

1 reference

4 September 2017

1 reference

3

Ariela Benigni

1 reference

4 September 2017

Carlamaria Zoja

1

1 reference

PubMed ID

26209738

4 September 2017

Cristina Zanchi

series ordinal

2

1 reference

PubMed ID

26209738

4 September 2017

language of work or name

English

0 references

publication date

1 August 2015

1 reference

Nephrology Dialysis Transplantation

4 September 2017

1 reference

4 September 2017

30 Suppl 4

1 reference

4 September 2017

iv54-9

1 reference

Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease

4 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Overview of the FGF23-Klotho axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Klotho depletion contributes to increased inflammation in kidney of the db/db mouse model of diabetes via RelA (serine)536 phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Genetic deficiency of anti-aging gene klotho exacerbates early nephropathy in STZ-induced diabetes in male mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Imaging of the porous ultrastructure of the glomerular epithelial filtration slit

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Activation of a local tissue angiotensin system in podocytes by mechanical strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

The Notch pathway in podocytes plays a role in the development of glomerular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Modulation of notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Interplay between the Notch and PI3K/Akt pathways in high glucose-induced podocyte apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

New player on an old field; the keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

When NRF2 talks, who's listening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

The extinguished BEACON of bardoxolone: not a Monday morning quarterback story

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

New therapies for diabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

The Nrf2 pathway in the progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Endothelin ETA receptor antagonism in cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Endothelin and endothelin antagonists in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Endothelin in chronic proteinuric kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Role of the JAK/STAT signaling pathway in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Suppressors of cytokine signaling abrogate diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV036

21 January 2018

Identifiers

DOI

10.1093/NDT/GFV036

1 reference

4 September 2017

1 reference

PubMed ID

26209738